What is the minimum age for cefdinir (Omnicef) administration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Minimum Age for Cefdinir Administration

Cefdinir is approved for use in pediatric patients 6 months of age and older. 1

FDA-Approved Age Indication

  • The FDA drug label explicitly states that "safety and efficacy in neonates and infants less than 6 months of age have not been established" 1
  • This 6-month minimum age applies to all approved indications for cefdinir, including respiratory tract infections, acute otitis media, pharyngitis/tonsillitis, and uncomplicated skin infections 1

Clinical Trial Evidence Supporting This Age Cutoff

  • Multiple pediatric clinical trials have enrolled patients starting at 6 months of age, establishing safety and efficacy data from this age forward 2, 3
  • A comparative study of cefdinir versus amoxicillin/clavulanate for acute otitis media specifically included children "ages 6 months to 12 years," with demonstrated clinical success rates of 80-83% 2
  • A skin infection study in pediatric patients enrolled children "aged 6 months to 12 years," showing clinical cure rates of 98.3% with good tolerability 3

Dosing Considerations for Infants 6 Months and Older

  • For infants and children 6 months through 12 years, the American Academy of Pediatrics recommends 7 mg/kg every 12 hours (twice daily) or 14 mg/kg every 24 hours (once daily) depending on the indication 4
  • The twice-daily regimen (7 mg/kg every 12 hours) is preferred for more serious infections or when treating β-lactamase-producing Haemophilus influenzae 4
  • The once-daily option (14 mg/kg every 24 hours) is effective for acute otitis media, sinusitis, and pharyngitis/tonsillitis 4

Clinical Context and Positioning

  • Cefdinir serves as an alternative agent when first-line therapy (such as amoxicillin or amoxicillin-clavulanate) cannot be used 5, 4
  • The Infectious Diseases Society of America positions cefdinir alongside cefixime, cefpodoxime, and ceftibuten as alternatives for treating β-lactamase-producing Haemophilus influenzae in community-acquired pneumonia 5, 4

Important Safety Considerations

  • Do not use cefdinir in infants younger than 6 months due to lack of established safety and efficacy data 1
  • Cefdinir can be administered with iron-fortified infant formula without significant pharmacokinetic interactions 1
  • However, iron supplements should be taken at least 2 hours before or after cefdinir to avoid decreased absorption 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.